Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences, Inc. (SGHT) Form 144 summary: The filing notifies a proposed sale of 19,948 common shares through Fidelity Brokerage Services with an approximate aggregate market value of $65,750.60. The sale is scheduled for 10/02/2025 on NASDAQ and the issuer reports 52,367,359 shares outstanding. The shares were acquired on 09/30/2025 through restricted stock vesting and were recorded as compensation. The filer also disclosed a prior sale of 19,260 shares on 07/02/2025 that generated $78,933.26 in gross proceeds. The notice includes the standard signature representation that the seller is unaware of undisclosed material adverse information.
Sight Sciences, Inc. (SGHT) Form 144 filing reports a proposed sale of 24,441 common shares through Fidelity Brokerage Services LLC on Nasdaq. The shares were acquired by restricted stock vesting on 09/30/2025 and are identified as compensation. The filer reports 52,367,359 shares outstanding for the class, and records an approximate aggregate market value of $81,740.48 for the shares to be sold with an approximate sale date of 10/01/2025. The filing also discloses that Paul Badawi sold 23,637 common shares on 07/01/2025 for gross proceeds of $98,133.73. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Sight Sciences entered a third amendment to its senior secured term loan with Hercules Capital, which allows borrowing of up to $65.0 million in total. The amendment adds another six months to the interest-only period, which now runs until February 1, 2027, giving the company more time before it must start repaying principal.
The change also reallocates an undrawn and unavailable $10.0 million tranche so that the amount the company can draw during the interest-only period increases from $15.0 million to $25.0 million, in minimum increments of $5.0 million, subject to approval by Hercules’ investment committee. In return for these changes, Sight Sciences paid Hercules a $50,000 fee plus certain costs and expenses.
Sight Sciences (SGHT) Form 144 shows a proposed sale of 20,753 common shares through Fidelity Brokerage Services, with an aggregate market value of $73,350.73 and an approximate sale date of 09/23/2025. The filer reports acquiring 5,753 shares on 10/16/2024 and 15,000 shares on 10/17/2024 via restricted stock vesting as compensation. The filing also discloses prior sales by the same person, Matthew Link: 4,889 shares on 07/02/2025 (gross proceeds $20,036.59), and three September 2025 sales totaling 60, - 10,000 shares (9/12/2025), 15,990 shares (9/16/2025), and 20,000 shares (9/19/2025) with reported gross proceeds shown in the filing.
Sight Sciences, Inc. (SGHT) Form 144 notifies of a proposed sale of 20,000 common shares through Fidelity Brokerage Services with an aggregate market value of $73,400. The notice lists the approximate sale date as 09/19/2025 and reports 52,367,359 shares outstanding, showing the planned sale relative to total equity.
The shares were originally acquired by the holder via restricted stock vesting on 10/16/2024 as compensation. The filing also discloses recent sales by the same person, Matthew Link: 4,889 shares on 07/02/2025 for $20,036.59, 10,000 shares on 09/12/2025 for $35,227.21, and 15,990 shares on 09/16/2025 for $55,291.81. The filer certifies no undisclosed material adverse information.
Sight Sciences (SGHT) Form 144: An insider notified the SEC of a proposed sale of 15,990 common shares acquired via restricted stock vesting on 10/15/2024. The filing lists the broker as Fidelity Brokerage Services LLC and an approximate aggregate market value of $55,291.81 with an anticipated sale date of 09/16/2025 on NASDAQ. The filing also discloses two recent sales by the same person: 4,889 shares sold on 07/02/2025 for $20,036.59 and 10,000 shares sold on 09/12/2025 for $35,227.21. The shares to be sold were paid as compensation when vested and the filer attests they have no undisclosed material adverse information.
Catherine Mazzacco, a director of Sight Sciences, Inc. (SGHT), reported on Form 4 that on 09/11/2025 she transferred 37,492 shares of the company's common stock to the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023 for no consideration. The filing shows the Reporting Person remains a beneficiary of that Trust. After the reported disposition, the Form 4 lists 41,015 shares as beneficially owned following the transaction. The Form 4 was signed by an attorney-in-fact on 09/15/2025.
Sight Sciences reported that Brenton Taylor, EVP of Operations & R&D and a company officer, received a grant of 25,840 restricted stock units (RSUs) on September 2, 2025 under the 2021 Incentive Award Plan. Each RSU represents a contingent right to one share of common stock and the grant is described as equal to approximately $100,000 of common stock based on the closing price on the grant date. The RSUs vest in 16 equal quarterly installments beginning September 30, 2025 and continuing through June 30, 2029, subject to continued service; the RSUs have no expiration date. After the grant, the reporting person beneficially owns 185,840 shares (direct).
Sight Sciences, Inc. (SGHT) reported that Matthew Link, its Chief Commercial Officer, resigned effective 08/31/2025. The filing states that because of the resignation the reporting person is no longer subject to Section 16 obligations and will not file further Forms 4 or 5 for transactions in the issuer's equity. The Form 4 was signed by an attorney-in-fact on 09/03/2025.
Sight Sciences, Inc. filed an insider report indicating that EVP of Research & Development Manohar K. Raheja is no longer a Section 16 insider. Effective August 31, 2025, his employment with the company terminated.
Because of this change, he will no longer be required to report transactions in Sight Sciences equity securities on Form 4 or Form 5. The filing does not list any specific stock transactions in its tables, focusing instead on the change in his reporting status.